French biotech company Alaxia has announced a collaboration with the Department of Molecular Medicine (DMM) at the University of Padua for in vitro testing of its ALX-009 hypothiocyanite / lactoferrin inhalation solution against SARS-CoV-2 as a possible treatment for COVID-19. The company has been developing ALX-009 as an inhaled antimicrobial for the treatment of … [Read more...] about Alaxia partners with University of Padua to evaluate ALX-009 inhalation solution against SARS-CoV-2
Business
Teva launches AirDuo Digihaler and ArmonAir Digihaler in the US
Teva Respiratory has launched its AirDuo Digihaler fluticasone propionate / salmeterol and ArmonAir Digihaler fluticasone propionate DPIs in the US, the company said. The company announced the launch of its ProAir Digihaler albuterol sulfate DPI in July 2020. AirDuo Digihaler was approved by the FDA for the treatment of asthma in July 2019, and the agency approved … [Read more...] about Teva launches AirDuo Digihaler and ArmonAir Digihaler in the US
Perrigo announces US recall of albuterol MDIs
Perrigo said that the company stopped production and distribution of its albuterol sulfate metered dose inhalers in the US and has issued a recall of the MDIs "out of an abundance of caution as a result of complaints that some units may not dispense due to clogging." The company noted that the inhalers are manufactured by Catalent Pharma Solutions and said that there … [Read more...] about Perrigo announces US recall of albuterol MDIs
Starpharma says tests show its astodrimer sodium nasal spray formulation effectively inactivates SARS-CoV-2
Starpharma has announced that testing of its SPL7013 astodrimer sodium intranasal formulation at the Scripps Research Institute demonstrated that the formulation inactivated nearly 100% of SARS-CoV-2 with low cellular toxicity. The company already markets several astodrimer sodium products under the VivaGel brand in a number of countries, including a VivaGel condom … [Read more...] about Starpharma says tests show its astodrimer sodium nasal spray formulation effectively inactivates SARS-CoV-2
Seelos Therapeutics gets Japanese patent for intranasal racemic ketamine
According to Seelos Therapeutics, the Japanese Patent Office has issued Japanese patent number 6722453, titled "Anxiolytic Composition, Formulation and Method of Use," covering the company's SLS-002 intranasal racemic ketamine formulation for treatment of anxiety due to phobias. In addition, the company said that it received a notice of allowance for Japanese patent … [Read more...] about Seelos Therapeutics gets Japanese patent for intranasal racemic ketamine
Destiny Pharma and SporeGen get £800,000 grant for bacillus nasal spray for prevention of COVID-19
Destiny Pharma and SporeGen have agreed to co-develop a bacillus nasal spray as a prophylactic for prevention of COVID-19, with much of the project cost covered by an £800,000 grant from Innovate UK. Pan Group subsidiary Huro will develop and manufacture the formulation, and the companies say that they expect to begin clinical trials by early 2022. Preclinical … [Read more...] about Destiny Pharma and SporeGen get £800,000 grant for bacillus nasal spray for prevention of COVID-19
Diomics licenses Active Motif antibodies for COVID-19 nasal spray
US biotech Diomics Corporation has announced plans to develop a prophylactic nasal spray against COVID-19 using antibodies licensed from Active Motif. According to the company, the Dioguard nasal spray, currently in in vitro testing, uses nanobeads made from the company's Diomat biopolymer loaded with Active Motif's 414-1 human IgG monoclonal antibodies. Diomics … [Read more...] about Diomics licenses Active Motif antibodies for COVID-19 nasal spray
Savara discontinues development of Molgradex for NTM lung infections
Savara has discontinued development of Molgradex inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of nontuberculous mycobacterial (NTM) lung infection and will not restart the Phase 2a ENCORE study of Molgradex for NTM in cystic fibrosis patients, the company said. Development of Molgradex for the treatment of … [Read more...] about Savara discontinues development of Molgradex for NTM lung infections
Iconovo gets US patent covering the ICOres DPI
Swedish DPI company Iconovo said that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance regarding a patent covering Iconovo’s ICOres reservoir-based dry powder inhaler. The patent, titled "Dry Powder Inhaler," describes the design of the ICOres device. The company was granted a Japanese patent for ICOres in November 2019 and has … [Read more...] about Iconovo gets US patent covering the ICOres DPI
Bilim Pharmaceuticals launches Ventofor Combi Fix, delivered by the PowdAir Plus DPI
H&T Presspart and Hovione Technology have revealed their collaboration with Bilim Pharmaceuticals on a dry powder inhaler based on the PowdAir Plus device. H&T Presspart acquired global rights to the capsule based DPI device from Hovione Technology in 2017. According to the announcement, Bilim has launched the Ventofor Combi Fix budesonide/formoterol DPI for … [Read more...] about Bilim Pharmaceuticals launches Ventofor Combi Fix, delivered by the PowdAir Plus DPI